Variable, mean (S.D) | Week 0 | Week 16 | Week 24 | Week 48 |
---|---|---|---|---|
Guselkumab response continuation; bio-naïve patients | ||||
Treatment received | Guselkumab | Re-randomized to guselkumab at week 28 | ||
NAPSI | 4.5 (1.9) | 2.5 (2.2) | 1.8 (2.0) | 1.2 (1.7) |
n | 85 | 83 | 84 | 82 |
PASI | 22.1 (8.4) | 1.2 (2.2) | 0.6 (1.0) | 1.0 (1.8) |
n | 85 | 85 | 85 | 83 |
Guselkumab response continuation; bio-experienced patients | ||||
Treatment received | Guselkumab | Re-randomized to guselkumab at week 28 | ||
NAPSI | 4.1 (1.6) | 2.0 (2.1) | 1.7 (2.1) | 0.9 (1.3) |
n | 23 | 23 | 23 | 23 |
PASI | 24.3 (10.0) | 1.2 (1.7) | 0.8 (1.5) | 2.5 (6.6) |
n | 23 | 23 | 23 | 23 |
Guselkumab response withdrawal; bio-naïve patients | ||||
Treatment received | Guselkumab | Re-randomized to placebo at week 28 | ||
NAPSI | 4.8 (2.0) | 2.5 (2.0) | 1.6 (1.9) | 1.8 (2.2) |
n | 81 | 80 | 80 | 80 |
PASI | 22.8 (9.2) | 1.2 (2.4) | 0.5 (1.4) | 5.0 (6.1) |
n | 85 | 85 | 84 | 84 |
Guselkumab response withdrawal; bio-experienced patients | ||||
Treatment received | Guselkumab | Re-randomized to placebo at week 28 | ||
NAPSI | 5.9 (1.8) | 2.3 (1.4) | 2.3 (2.0) | 2.3 (1.7) |
n | 16 | 16 | 16 | 16 |
PASI | 24.4 (8.3) | 2.0 (3.6) | 0.9 (0.8) | 6.4 (6.0) |
n | 16 | 16 | 16 | 16 |